| Literature DB >> 26531700 |
Silje Stokke Kvistad1, Kjell-Morten Myhr2, Trygve Holmøy3, Jūratė Šaltytė Benth4, Stig Wergeland5, Antonie G Beiske6, Kristian S Bjerve7, Harald Hovdal8, Finn Lilleås9, Rune Midgard10, Tom Pedersen11, Søren J Bakke12, Annika E Michelsen13, Pål Aukrust14, Thor Ueland15, Jørn V Sagen16, Øivind Torkildsen2.
Abstract
Obesity is a possible risk factor of multiple sclerosis (MS), but the association between obesity and MS disease activity has not been explored. In a cohort of 86 MS patients, 80% of overweight or obese patients (BMI≥25kg/m(2)) had MRI activity compared to 48% of the normal-weight patients (BMI<25kg/m(2)) (p=0.001) during interferon-beta treatment. NEDA-status (no evidence of disease activity) was defined as a composite that consisted of absence of any relapses, sustained disability-progression and MRI-activity. Among normal-weight patients 26% obtained NEDA-status compared to only 13% of patients with BMI >25 (p=0.05). This may indicate that BMI affects interferon-beta treatment response.Entities:
Keywords: Body mass index (BMI); Interferon-beta treatment; MRI disease activity; Multiple sclerosis; No evidence of disease activity; Treatment response
Mesh：
Substances：
Year: 2015 PMID： 26531700 DOI： 10.1016/j.jneuroim.2015.09.008
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478